19th Apr 2018 13:59
LONDON (Alliance News) - Motif Bio PLC on Thursday said iclaprim delivered further positive results as part of its REVIVE-2 phase three trial.
Motif Bio previously had said iclaprim showed a better primary endpoint results than the current standard of care, vancomycin.
Iclaprim is a proposed treatment for bacterial skin and skin structure infections.
However, more detailed results show iclaprim was "well tolerated" in the trial, and 75% of adverse events were mild. Blood levels of serum creatinine, which measures kidney function, were not affected by iclaprim use.
No deaths were reported in iclaprim compared to one in vancomycin.
The drug, it said, also has the potential to avoid costs related to vancomycin-associated kidney damage.
Shares were up 2.3% on Thursday at 35.05 pence each.
Related Shares:
MTFB.L